What question did this study set out to answer?

To investigate the effects of GLP-1 receptor agonists on stroke risk and mortality in patients with moyamoya disease and type 2 diabetes mellitus.

April 13, 2026

Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus

Key Points

To investigate the effects of GLP-1 receptor agonists on stroke risk and mortality in patients with moyamoya disease and type 2 diabetes mellitus.
Analyzed clinical outcomes in patients with moyamoya disease and type 2 diabetes
Assessed stroke, intracerebral hemorrhage, and death rates
Examined treatment with GLP-1 receptor agonists
Patients using GLP-1 receptor agonists had lower rates of stroke
Incidence of intracerebral hemorrhage was reduced
Mortality rates among these patients declined

Abstract

In this study, patients with MMD and T2DM who were prescribed a GLP-1 receptor agonist had lower risk of stroke, ICH, and death. Prospective studies and randomized controlled trials are needed to clarify the role of GLP-1 receptor agonists in the management of MMD.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Joanna M. Roy

Basel Musmar

Ramsay Hafer

Journals

Journal of neurosurgery

Actions

Institutions

Neurological Surgery

Thomas Jefferson University Hospital

Rowan University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Glucagon-like peptide-1 receptor agonists in patients with moyamoya disease and type 2 diabetes mellitus

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider